Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Recruiting N/A Interventional Study
Advanced Malignant Solid Tumors
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
The First Affiliated Hospital of Nanchang University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * With inoperable advanced malignant solid tumors, including melanoma, gastrointestinal tumor, breast cancer, pancreatic cancer, cervical cancer, lung cancer, etc. * Failed in standard treatment or voluntarily give up other treatment, and been longer than 2 weeks from the end of…
Contacts

Sujun Li, PhD

8617600699826

17600699826@163.com

CONTACT

Aiping Le

CONTACT